Mandate

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 546 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Jefferies International Limited, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Johan Winnerblad, Rikard Lindahl and Hampus Olsson.

Related

Vinge advises Adelis Equity Partners on the establishment of a continuation fund

Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equity Partners Fund II. The continuation fund is a so-called dual-asset vehicle which will invest in Presto and HVD Group (Hantverksdata) – both current portfolio companies of Adelis Equity Partners Fund II. The continuation fund, in which HarbourVest Partners will be the largest investor, will have EUR 430m in commitments and will invest alongside Adelis Equity Partners Fund III and the Adelis team.
February 21, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Wavecon

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Wavecon AB (”Wavecon”).
February 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Projektstaben

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Projektstaben i Sverige AB (”Projektstaben”).
February 14, 2024